India’s Growing Diabetes and Heart Failure Burden

Scope and clinical significance

India now faces a substantial diabetes burden, with an estimated 101 million people living with type 2 diabetes mellitus (T2DM). This high prevalence carries a parallel rise in cardiovascular complications, particularly heart failure (HF). Nearly half of individuals with T2DM in India are affected by HF, creating a dual clinical challenge that complicates management, increases morbidity, and places added strain on healthcare systems.

Why obesity matters more than glycaemia for HF risk in T2DM

Comparing BMI and HbA1c as predictors of heart failure

People with T2DM carry a two- to fivefold higher cardiovascular risk overall, with more than half of mortality in this population attributable to cardiovascular disease. While progressive increases in HbA1c are associated with higher HF risk, body mass index (BMI) has been shown to outperform HbA1c in predicting HF events. Quantitatively, each 1 kg/m² increase in BMI corresponds to a 5–7% increase in HF risk, and every 5-unit rise in BMI is linked to approximately a 41% higher HF risk. Observational evidence indicates that in the absence of excess adiposity, diabetes alone is not consistently associated with heart failure with preserved ejection fraction (HFpEF). This pattern supports the conclusion that obesity—particularly visceral adiposity—is the dominant driver of HF risk among people with T2DM.

Clinical consequences for obese T2D-HFpEF patients

Among patients with both obesity and T2DM who develop HFpEF, clinical outcomes are worse: greater exercise intolerance, higher rates of HF-related hospitalizations, and poorer overall prognosis have been documented. These findings underscore the importance of identifying and addressing adiposity as a principal therapeutic target in this subgroup.

Pathophysiology: how hyperglycaemia and adiposity drive heart failure

Hyperglycaemia-related maladaptive pathways

Hyperglycaemia contributes to cardiac dysfunction through multiple maladaptive biochemical pathways. These include activation of the hexosamine, polyol, and pentose phosphate pathways and the accumulation of advanced glycation end products (AGEs). These mechanisms promote structural and functional myocardial changes that increase vulnerability to HF.

Visceral adiposity as the predominant mechanistic driver

Visceral fat exerts several direct and indirect effects on the heart that together make it the principal mechanistic driver of diabetes-associated HF. Adipose tissue dysregulation produces an adverse adipokine profile, fosters cardiac steatosis (fat deposition within the myocardium), and can impose pericardial constraint—mechanical and inflammatory processes that promote adverse cardiac remodeling. These adiposity-related effects often act in concert with hyperglycaemia to accelerate HF development and progression.

Impact of weight reduction on heart failure incidence in obese T2DM

Evidence from randomized trials and surgical cohorts

Clinical evidence supports a meaningful reduction in incident HF when weight loss is achieved among overweight and obese adults with T2DM. In a sub-analysis of the Look AHEAD trial, a 10% reduction in BMI over one year and sustained over four years was independently associated with 31% and 20% reductions, respectively, in incident HF. Similarly, data from a major cardiovascular outcomes trial of subcutaneous semaglutide (SELECT) showed that an average 8.5% weight loss mediated by semaglutide injections was associated with an 18% reduction in a heart-failure-related composite endpoint (hazard ratio 0.82; 95% CI 0.71–0.96). Retrospective analyses of bariatric surgery cohorts provide further support: Roux-en-Y gastric bypass, associated with a mean ~30% BMI reduction at five years, correlated with a 62% reduction in incident HF (HR 0.38; 95% CI 0.22–0.64).

Clinical implications of these magnitude effects

These consistent, magnitude-consistent findings across behavioral, pharmacologic, and surgical interventions indicate that weight reduction yields proportional cardiometabolic benefits for obese patients with T2DM. The data suggest that modest (5–10%) to substantial (≥10%) BMI reductions translate into measurable decreases in HF incidence and related morbidity.

Guideline endorsements for weight-targeted HF management in T2DM

Current recommendations from major bodies

Recent guideline statements emphasize weight reduction as an integral component of HF care in patients with obesity and T2DM. The national Standard Treatment Workflow for Heart Failure (January 2026) recommends incorporating weight-reduction strategies across all levels of care, from primary health centres through tertiary hospitals. Parallel guidance from the Heart Failure Society of America’s Scientific Statements Committee recommends a target of at least 5%–10% weight loss for patients with HF and BMI ≥35 kg/m². The Heart Failure Association of India’s 2025 diagnostic and management guideline also advises weight-reduction strategies and specifically cites evidence that semaglutide reduced HF hospitalizations in trials that reduced obesity. In 2025, a major cardiology college’s scientific statement on managing obesity in adults with HF highlighted that among glucagon-like peptide-1 receptor agonists (GLP-1 RAs), injectable semaglutide showed improvements in symptoms, functional capacity, quality of life, and weight reduction in trials enrolling people with BMI ≥30 kg/m². National guidance issued in early 2026 similarly recommends subcutaneous semaglutide as part of initial triple therapy in people with T2DM and established atherosclerotic cardiovascular disease, alongside metformin and an SGLT2 inhibitor.

Broader integration of GLP-1 receptor agonists in T2D-HF care

Potential role of injectable semaglutide

As access to GLP-1 receptor agonists expands, injectable semaglutide is positioned to play a significant role in managing patients with T2DM and concurrent HF. Trial evidence indicates that semaglutide reduces cardiovascular death, heart failure events, and non-fatal myocardial infarction by an estimated 20% (SELECT; HR 0.80). In addition to cardiovascular event reduction, semaglutide has been associated with reductions in NT-proBNP—an established biomarker of cardiac stress—and sustained weight loss. Collectively, these effects target the obesity–inflammation–cardiac remodeling triangle that underpins HF progression in T2DM.

Key takeaways for clinicians and health systems

– India’s 101 million adults with T2DM face a substantial and compounding heart failure burden, with HF affecting nearly half of individuals with diabetes; obesity emerges as a dominant modifiable driver.
– Visceral adiposity contributes to HF through adipokine imbalance, cardiac steatosis, and pericardial constraint; hyperglycaemia amplifies maladaptive cardiac signaling via pathways such as AGE formation and hexosamine activation.
– Weight loss delivers proportional cardiometabolic benefits: a 10% BMI reduction corresponded to a 31% reduction in incident HF in one analysis; semaglutide-mediated 8.5% weight loss yielded an 18% reduction in a HF composite endpoint; bariatric surgery with substantial BMI loss was associated with a 62% reduction in incident HF.
– Major guideline bodies recommend weight-targeted interventions as a cornerstone of HF management in obese patients with T2DM.
– Integrating GLP-1 RAs—particularly injectable semaglutide—into therapeutic strategies has the potential to address the mechanistic drivers of HF in T2DM and to improve clinical outcomes when deployed appropriately alongside established therapies.

Abbreviations

ACC, AGE, BMI, CAD, CHC, CI, CVD, GLP-1 RA, HbA1c, HF, HFAI, HFSA, HFpEF, HR, ICMR, MI, NICE NG28, NT-proBNP, PHC, RYGB, SGLT2i, STW, T2D/T2DM